


[NIDDK Home](#)
[Welcome](#)
[Health Information](#)
[Research Funding Opportunities](#)

- [Research Areas NIDDK Will Fund](#)
- [Current Funding Opportunities](#)
- [NIDDK Funding Policy](#)
- [Conferences & Workshops](#)
- [Division Organization](#)
- [Research Training & Career Development](#)
- [Research Centers](#)
- [Grants & Contracts Processes](#)
- [Grantee Responsibilities](#)
- [Grant Review Information](#)
- [Research Tools & Resources](#)

[Clinical Research](#)
[NIDDK](#)

United States  
**National Institute of Diabetes & Digestive & Kidney Diseases**  
 of the National Institutes of Health

[Site Map](#) • 
 [Frequently Asked Questions](#) • 
 [Contact NIDDK](#) •

[> Advanced Search](#)

[NIDDK Home](#) : 
 [Research Funding Opportunities](#) : 
 [Resources for Type 1 Diabetes Investigators](#) : 
 [Availability of Biosamples from the Genetics of Kidneys in Diabetes \(GoKinD\) Study](#)

## Resources for Type 1 Diabetes Investigators

The Genetics of Kidneys in Diabetes (GoKinD) collection has nearly 10,000 DNA, serum, plasma and urine samples, plus genetic and clinical data, from more than 1,700 adults with type 1 diabetes in the United States and Canada. Of those, 818 have had diabetes at least 10 years and have developed kidney disease, a common complication of diabetes. The other 893 have had diabetes at least 15 years but do not have kidney disease. Also in the collection are data and samples from 1,096 parents (548 sets).

Researchers can apply for DNA, extensive clinical data and some genetic data from GoKinD at <http://www.gokind.org/access>; serum, plasma and urine samples will be made available later. Methods of treatment, insulin doses, complications, smoking history and other data have been documented for all GoKinD participants. Also, DNA has been genotyped for genes well-known to predispose to type 1 diabetes. To protect the privacy of patients and families, researchers do not have access to names and other identifying information.

Both NIH and JDRF will separately consider requests to fund research on GoKinD data and samples. NIH grant applications are at <http://grants.nih.gov>, and resources for type 1 diabetes research are listed at [www.niddk.nih.gov/fund/diabetesspecialfunds/funding.htm](http://www.niddk.nih.gov/fund/diabetesspecialfunds/funding.htm). JDRF grant applications are under the research tab at [www.jdrf.org](http://www.jdrf.org).

NIH, JDRF and CDC collaborated on GoKinD. NIH supported the study through a special fund for type 1 diabetes research established by Congress in 1997 and coordinated by



Genetics of Kidneys in Diabetes Study

[gokindinfo@gokind.org](mailto:gokindinfo@gokind.org)

[About the GoKinD Study](#)

[Eligibility Criteria](#)

[About the GoKinD Collection](#)

[Access to the Collection](#)

[Type 1 Diabetes Study Links](#)

### About the GoKinD Study

The purpose of the Genetics of Kidneys in Diabetes (GoKinD) Study is to establish a repository of DNA and clinical information from adults with long-term Type 1 diabetes, with or without kidney disease, along with their parents. The fundamental aim of GoKinD is to facilitate investigator-driven research into the genetic basis of diabetic kidney disease as well as other issues concerning Type 1 diabetes. This clinically well-characterized population provides a scientific resource maintained under the joint stewardship of JDRF, the Joslin Diabetes Center, GWU and CDC. All collaborating organizations are committed to establishing and maintaining access to the data set as much as is feasible.

Recruitment of new families for the study is closed as of November 2004. In the three and a half years of the recruitment phase the GoKinD study has screened more than 5500 participants by phone and in person.

[CLICK HERE](#) for more information about recruitment.

[CLICK HERE](#) for a list of GoKinD principal investigators.

# GoKinD Participants

- Cases:

Adult, 18-54, living in US or Canada

Type 1 diabetes at least 10 years, with kidney disease

Persistent proteinuria (2/3 ACRs  $>300$   $\mu\text{g}/\text{mg}$ ) or ESRD

- Controls:

Adult, 18-59, living in US or Canada

Type 1 diabetes at least 15 years, without kidney disease

Has never been treated with ACE inhibitors, no current anti-hypertensive medication

Normoalbuminuria (2/3 ACR  $< 20$   $\mu\text{g}/\text{mg}$ )

- All trios are complete – 2 living parents.

- Last study IDs issued Oct. 31, 2004

## GoKinD Characteristics Tables as of 7 March 2005

---

Case trios = 267; Case singletons = 627    Total cases = 894

Control trios = 317; Controls = 618    Total controls = 935

Final eligibility calls will be made March 31, 2005.

# GoKinD Participant Samples

- Clinical Data
- Genetic data limited to: HLA (DRB1, DQA1, DQB1), INS
- DNA
- Cryopreserved lymphocytes
- Serum
- Plasma
- Urine
- Immortalized cell line (EBV-transformed)
- DNA samples will be distributed in August 2005

# GoKinD Clinical Data

Race	ESRD	Age at diabetes
Gender	Non-ESRD:	Diabetes duration
Age at Entry	ACR	Pancreas transplant?
BMI	GFR (MDRD, C-G)	Insulin regimen
Waist Circumference	100/creatinine	HbA1c (%)
Smoking (Ever/current)	100/cystatin C	Other autoimmune disease
Serum Total Cholesterol	Hypertension	
HDL-cholesterol	Antihypertensive Treat.	
Serum creatinine	Blood Pressure	
Serum cystatin C	Living Parents	
Urine albumin	Retinopathy	
Urine creatinine	Cardiovascular Disease	
	Neuropathy	

# GoKinD Clinical QC Data (11/8/2004 data)

Test	n	Coefficient of Reliability (95% Confidence Interval)
Blood Hemoglobin A <sub>1c</sub>	128	0.9891 (0.9846 - 0.9923 )
Serum Total Cholesterol	111	0.9613 (0.9442 - 0.9732)
Serum HDL-cholesterol	103	0.9667 (0.9512 - 0.9773)
Serum Creatinine	108	0.9926 (0.9892 - 0.9949)
Serum Cystatin C	74	0.9731 (0.9576 -0.9829)
Urine Albumin	111	0.934 (0.9055 - 0.9542)
Urine Creatinine	111	0.9467 (0.9234 - 0.963)
Albumin/Creatinine Ratio	111	0.9126 (0.8753 - 0.9391)

Replicate samples from 10% of participants were used as QC. CBL processed blind duplicate samples. All aspects of process were QC'ed.

# GoKinD Informed Consent

- Samples may be used for the study of the genetic risk factors for Type 1 diabetes and its complications
- Samples and information will be shared: “we will give your DNA or other cell parts to researchers”
- No cell lines will be distributed.
- Results of standard medical tests returned to the patient, but no information from DNA or cells
- No identifying information will be released.
- No guarantee of personal benefit and no expectation of personal profit
- Voluntary withdrawal at any time
- Consent for future contact (follow up)



# Requests for Access

- Requests will be considered by separate Access Committee
- Criteria for access:
  - Scientific rationale
  - Amount of DNA requested
  - Appropriate study design
  - QC plan adequate
  - Appropriate Use
  - Environment and facilities
  - Plan for handling data
  - IRB FWA number
- Review of requests for access of renewable material **will not** consider scientific merit.

# Requirements for Approved Investigators

- Agree to report all data generated using GoKinD samples back to GoKinD database (12 months)
- Agree to provide documentation of IRB approval
- Agree to comply with the provisions of informed consent
- Agree to conduct the research indicated in the approved request
- Agree not to identify or attempt to identify individual participants
- Agree not to distribute GoKinD materials to third parties
- Agree not to use GoKinD materials in human experimentation
- Agree to provide funders with copies of publications
- Agree to acknowledge GoKinD

# Other Populations

NIH-supported:

EDIC

FIND – T1 and T2

EU-supported:

EUROGEDIC

EURODIAB

Diabetes UK- and JDRF-supported:

Warren III (GoKinD UK)

Wellcome Trust- and JDRF-supported:

Nephropathy Family Study

# GoKinD Organization

## Executive Committee:

Joslin Diabetes Center (Warram, Rogus, Krolewski)

George Washington University Bioinformatics Center (Cleary)

Centers for Disease Control (Cordovado, Mueller)

University of Minnesota (Steffes, Bucksa)

Matthews Media Group

JDRF

## Steering Committee:

Steve Bain, M.D.; Birmingham

Josephine Briggs, M.D.; NIDDK

Soumitra Ghosh, Ph.D.; MCW

Michael Mauer, M.D.; Minnesota

Steve Rich, Ph.D.; WFU

Richard Spielman, Penn

John Todd, Ph.D.; Cambridge

JDRF Lay Reviewers – Adelman, Emerson, Loew, Perry, Silvestri